Literature DB >> 8145232

[D-TRP32]neuropeptide Y: a competitive antagonist of NPY in rat hypothalamus.

A Balasubramaniam1, S Sheriff, M E Johnson, M Prabhakaran, Y Huang, J E Fischer, W T Chance.   

Abstract

Neuropeptide Y (NPY) is a potent orexigenic peptide. Structure-activity studies have revealed that nearly the entire sequence of NPY is required to elicit feeding responses. Therefore, in order to develop antagonistic peptides for NPY-induced feeding, we synthesized full-length analogs of NPY, substituting D-Trp in the C-terminal receptor binding region, and screened their activity in rat hypothalamus. Although [D-Trp36]NPY and [D-Trp34]NPY inhibited isoproterenol-stimulated hypothalamic membrane adenylate cyclase activity, [D-Trp32]NPY exhibited no intrinsic activity. Furthermore, [D-Trp32]NPY inhibited [125I]NPY binding to rat hypothalamic membranes with a potency comparable to that of NPY. The presence of 30 and 300 nM concentrations of [D-Trp32]NPY shifted the inhibitory dose-response curve of NPY on isoproterenol-stimulated hypothalamic membrane adenylate cyclase activity parallel to the right with comparable KB values. Moreover, in vivo experiments in rats revealed that [D-Trp32]NPY (10 micrograms) significantly attenuated the 1-h feeding response induced by NPY (1 microgram). Several other substitutions at position 32 including 2-D-Nal resulted in agonist activity, suggesting that there are strict structural requirements to induce the antagonistic property in NPY. These findings confirm that [D-Trp32]NPY is a competitive antagonist of NPY in both in vitro and in vivo systems. Analogs based on [D-Trp32]NPY may have potential clinical application, since NPY has been implicated in the pathophysiology of a number of feeding disorders including obesity, anorexia, and bulimia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8145232     DOI: 10.1021/jm00032a015

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Substitution of D-Trp32 in NPY destabilizes the binding transition state to the Y1 receptor site in SK-N-MC cell membranes.

Authors:  R Zand; C L Marcelo; R MacKenzie; L Georgic; D Maclean; W R Dunham
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

2.  Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release.

Authors:  C J Small; D G Morgan; K Meeran; M M Heath; I Gunn; C M Edwards; J Gardiner; G M Taylor; J D Hurley; M Rossi; A P Goldstone; D O'Shea; D M Smith; M A Ghatei; S R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

4.  Regulation of neurotransmission in the arcuate nucleus of the rat by different neuropeptide Y receptors.

Authors:  H Rhim; G A Kinney; P J Emmerson; R J Miller
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

5.  High-affinity neuropeptide Y receptor antagonists.

Authors:  A J Daniels; J E Matthews; R J Slepetis; M Jansen; O H Viveros; A Tadepalli; W Harrington; D Heyer; A Landavazo; J J Leban; A Spaltenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.